Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Children's Healthcare of Atlanta · Emory University · +22 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
497
total citations
- FWCI
- 36.66
- Percentile
- 100%
- References
- 35
Citations per year
Authors
34Topics & keywords
Topics
Keywords
- Neurofibromatosis
- Medicine
- Glioma
- Selumetinib
- Refractory (planetary science)
- Pediatrics
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.